PrecisionLife Announces New Appointments to Launch Diagnostics and Healthcare Strategy

2023-11-22

高管变更

Oxford, UK – 22 November 2023 – PrecisionLife®, a leading computational biology company focused on precision medicine in complex chronic diseases, announces the appointment of Dr Gerald Dunstan as SVP Corporate Development and Hannah Bibby as Product Strategy Lead to drive the company’s expansion into precision diagnostics and personalized healthcare. Gerald joins PrecisionLife as SVP Corporate Development working across both biopharma and healthcare. Gerald is a molecular biologist who received his PhD in Antimicrobial Drug Discovery under the Glaxo Scholarship Program. After several years working across drug discovery and development, Gerald transitioned into commercial roles where he has spent the last 25 years advising biopharma companies, healthcare providers and payers. He was a junior partner in McKinsey & Company’s healthcare and pharma products practice, and a co-founder and Board member of the McKinsey Hospital Institute. He led KPMG’s Healthcare & Life Sciences strategy practice and business units in Medtronic and GE Healthcare. Prior to joining PrecisionLife, Gerald served as Chief Strategy Officer at Prescient Healthcare Group. “I’m so impressed by the number and quality of pharma partnerships PrecisionLife has already established, and excited by the potential for so many more across a range of disease areas,” says Gerald. “There is huge untapped potential for the company’s technology and IP to be applied in healthcare, which we’re just starting to explore. It’s hard not to be excited by the impact this could make on the prediction and treatment of complex chronic diseases for patients.” Hannah joins PrecisionLife as Product Strategy Lead where she will translate the disease insights generated by the PrecisionLife platform into valuable new healthcare products. Hannah holds a Natural Sciences MA from the University of Cambridge and is completing a Master’s in Biomedical Informatics at Harvard Medical School. She has previously served in Owkin's Diagnostics Product Strategy team and as Strategy Consultant in L.E.K. Consulting's life science practice. “We’re delighted to welcome Gerald and Hannah to the PrecisionLife team at a time when our deep disease insights and patient stratification biomarkers are finding important new markets and bringing precision approaches to the early, more accurate diagnosis and care of patients with complex chronic diseases,” said Dr Steve Gardner, PrecisionLife CEO. “They will drive our collaborations with CROs, diagnostics and healthcare organizations to bring a new generation of simple, cost-effective and highly predictive tests to market in diseases like endometriosis, ME/CFS, long COVID and ALS where there is massive unmet medical need.” ENDS For further press information please contact: Noah Konig at PrecisionLife noah@precisionlife.com / +44 (0)1865 575170 About PrecisionLife PrecisionLife® is a pioneering computational biology company changing the way the world predicts, prevents, and treats chronic disease. With a vast repository of intellectual property and unique insights into the disease biology of over 50 indications, we have developed one of the most extensive drug discovery pipelines of precision targeted therapies. Our innovative combinatorial approach enables us to uncover the deepest causal insights into disease biology and achieve mechanism-based patient stratification even in the most heterogeneous conditions. This empowers us to inform and de-risk every stage of biopharma innovation, from initial concept to the clinic, and to identify secondary indications for existing programs - bringing new treatments to market faster. To learn more about our groundbreaking work, please visit precisionlife.com, connect with us on LinkedIn at @PrecisionLifeAI and follow us on Twitter at @PrecisionLifeAI.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构